Please login to the form below

Not currently logged in
Email:
Password:

Drug science

This page shows the latest Drug science news and features for those working in and with pharma, biotech and healthcare.

Building a brighter future for rare disease patients

Building a brighter future for rare disease patients

However, the Orphan Drug Act, passed in 1983, ushered in a new era for rare disease development. ... With cutting-edge science taking centre stage in orphan drug development, academic institutions and virtual biopharma play a central role in innovation.

Latest news

More from news
Approximately 1 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Keeping up the fight against HIV and using the lessons to tackle other threats Keeping up the fight against HIV and using the lessons to tackle other threats

    The strategy echoes its HIV heritage and continuing practice of working closely with patient groups in all aspects of drug development. ... A strong connection between science and society is vital and success is based on partnerships,” added Mr Elliott.

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    30 years, the continent has struggled to keep pace with the US, where the east and west coasts are runaway leaders in producing exciting new drug science. ... it into a drug candidate with commercial potential and taking it all the way to market with

  • The real-world data conundrum The real-world data conundrum

    This change is affecting all stakeholders. From a drug development perspective, a new data science is driving a paradigm shift in the product life cycle. ... Our best guess comes from the studies undertaken by the Tufts Center for the Study of Drug

  • When science is not enough When science is not enough

    Traditional pharma companies are all about natural science and drivers such as: ‘How can we do the most impressive natural science and develop the great drug.’ Our challenge to that is ... BEACON makes it easier for different stakeholders to

  • Interview: Joseph Jimenez, Novartis Interview: Joseph Jimenez, Novartis

    Our research strategy is unique; we focus on the science, not just market potential. ... Research at Novartis is centred on understanding the science of disease and drug targets and of molecular pathways that may be shared by multiple diseases.".

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • New hires at FibroGen, Saniona and Turbine New hires at FibroGen, Saniona and Turbine

    She is also a committee member of the Science Board to the US Food &Drug Administration. ... In that role, Barge oversaw the company’s acquisition of Kudos, which yielded the drug Lynparza (olaparib).

  • Bone Therapeutics strengthens board with new chairman Bone Therapeutics strengthens board with new chairman

    Thomas Lienard, chief executive officer of Bone Therapeutics, said: “Stéphenne has unparalleled experience in drug development and building innovative life science companies and is highly regarded within the sector.

  • Destiny Pharma appoints new CEO Destiny Pharma appoints new CEO

    Clark will also be a member of the firm’s board of directors after spending 20 years in private and public life science companies gaining international experience in drug research and ... As we move forward, Neil’s extensive leadership experience in

  • DiCE Molecules adds Dr Richard Scheller to its board of directors DiCE Molecules adds Dr Richard Scheller to its board of directors

    truly a visionary and a distinguished leader in oncology, neuroscience, immunology and infectious disease drug development. ... out our science and bring potential drug targets into the clinic.”.

  • Keith Webber leaves FDA for Perrigo Keith Webber leaves FDA for Perrigo

    Switches regulatory agency for biopharma company. Perrigo Company has named former US Food and Drug Administration (FDA) employee Keith Webber as head of its regulatory review process. ... Prior to this, he oversaw regulation of generic medicines at the

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics